• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Etrials Appoints Permanent CEO

Etrials Appoints Permanent CEO

November 14, 2008
CenterWatch Staff

Just a day after releasing disappointing third quarter results, Morrisville, N.C.-based eClinical company etrials named a new president and CEO, M. Denis Connaghan, replacing interim president and CEO Chuck Piccirillo. Piccirillo, who will resume his position as vice president of technology, has served as interim CEO since the resignation of Eugene “Chip” Jennings in July. Connaghan was formerly managing director within Marsh USA’s Global Operations.

Other personnel news from the clinical trials industry:

Oncology CRO Averion appointed Alison Messom, Ph.D., Global Head, Project Management. Messom will oversee all aspects of project management focusing on strategy, training and enhanced procedures within Averion’s Clinical Operations Management Team. Prior to joining the Southborough, Mass.-based company, Messom was executive director, Clinical Monitoring International, at i3 Research.

Kendle, WuXi Pharmatech and Encorium all appointed new board members. Kendle reappointed its former executive vice president and chief financial officer (CFO) Timothy Mooney to its board, effective immediately. Mooney served as CFO for Kendle from 1996 until his retirement in 2002. Chinese CRO WuXi appointed Ying Han, former CFO and executive vice president at Asiainfo, to its board of directors, and Wayne, Pa.-based Encorium named Shahab Fatheazam its newest board member. Fatheazam is currently a managing director and head of the U.S. healthcare practice of GCA Savvian, an international investment banking advisory firm.   

Gateway for Cancer Research, an international not-for-profit organization that funds translational clinical trials for cancer treatment, appointed Lynette Bisconti as the company’s new president. A breast cancer survivor, Bisconti served for several years as a member of the Patient Advisory Council at Cancer Treatment Centers of America and on the Y-ME National Breast Cancer Organization (now the Breast Cancer National Network of Strength).

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing